Author:
Yin Juanjuan,Li Zexuan,Hao Zedong,Yu Zhuanzhuan,Yu Weimin,Yang Guang,Ren Xiaojun
Abstract
Abstract
Background
Minimal change disease (MCD), a pathological type of nephrotic syndrome (NS), can occur in patients with tumors. We report two adult cases of MCD associated with papillary thyroid carcinoma (PTC), known to be extremely rare in adults.
Case presentation
A 35-year-old female patient was simultaneously diagnosed with MCD and PTC. The MCD was effectively treated with thyroidectomy and prednisone.In addition, a 50-year-old male patient, who had been diagnosed with PTC three years prior, had MCD confirmed by renal biopsy. The patient achieved complete remission following treatment with tacrolimus and rituximab.
Conclusions
The present case report describes and discusses the diagnostic and treatment processes employed in these two patients. Clinicians need to be aware of the renal effects of treating patients with solid tumors.
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Maas RJ, Nijenhuis T, van der Vlag J. Minimal change disease: more than a podocytopathy? Kidney Int Rep. 2022;7(4):675–7.
2. Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021;1(1):47–77.
3. Seitz-Polski B, Audard V, Ghiggeri GM, Tomas NM. Editorial: Immune dysfunction in nephrotic syndrome - recent advances and new roads ahead. Front Immunol. 2022;13:985925.
4. Koopman T, Niedlich-den Herder C, Stegeman CA, Links TP, Bijzet J, Hazenberg BPC, et al. Kidney involvement in systemic calcitonin amyloidosis associated with medullary thyroid carcinoma. Am J Kidney Dis. 2017;69(4):546–9.
5. Han ST, Choi SO, Song SH, Kim JS, Eom MS, Lee JI, et al. Membranoproliferative glomerulonephritis associated with papillary thyroid carcinoma. Korean J Nephrol. 2011;30(2):183–6.